NCT07166003Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Effects of Neoadjuvant Immunotherapy on Patients With Lung Cancer: a Prospective, Observational Study
Source: ClinicalTrials.gov · Last updated 10 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 3 Sept 2025
- Start date
- 20 Apr 2025
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Lung cancer
- NCT number
- NCT07166003
What you commit to
- Study type: Observational
- Planned participants: 500
- From 20 Apr 2025 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous anti-tumor therapies including chemotherapy or radiotherapy;
Other illness
- Diagnosed with or suspected active autoimmune diseases;
- History of organ transplantation or hematopoietic stem cell transplantation;
- Uncontrolled diabetes mellitus;
- Uncontrolled hypertension.
Lab values
- Presence of EGFR/ALK sensitive mutations;
Other
- Pregnant or breastfeeding women;
- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
Who the study is looking for
- Aged between 18 and 79 years;
- Received at least two cycles of neoadjuvant immunotherapy;
- ECOG performance status score of 0;
- Complete clinical information including imaging data available.
Age in the registry: 18 years to 79 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.